Predicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach

Abstract

BACKGROUND: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach.

AIM: To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection.

MATERIALS AND METHODS: The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow.

RESULTS: All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors.

The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model.

CONCLUSIONS: The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.

Keywords

HIV / COVID-19 / SARS-CoV-2

References

[1] Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acuteillness severity in the NHS. London: RCP; 2012.

[2] Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acuteillness severity in the NHS. London : RCP, 2012.

[3] Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi: 10.1016/j.jinf.2020.04.021

[4] Zheng Z., Peng F., Xu B., et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis // J Infect. 2020. Vol. 81, N 2. P. e16–e25. doi: 10.1016/j.jinf.2020.04.021

[5] Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020;9(2):428–436. doi: 10.21037/apm.2020.03.26

[6] Zhou Y., Zhang Z., Tian J., Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus // Ann Palliat Med. 2020. Vol. 9, N 2. P. 428–436. doi: 10.21037/apm.2020.03.26

[7] Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versii 3–18. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. [Internet]. (In Russ). Available at: https://minzdrav.gov.ru/ministry/med_covid19.

[8] Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версии 3–18 // Министерство здравоохранения Российской Федерации [интернет]. Режим доступа: https://minzdrav.gov.ru/ministry/med_covid19.

[9] Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328

[10] Wynants L., Van Calster B., Collins G.S., et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal // BMJ. 2020. Vol. 369. P. m1328. doi: 10.1136/bmj.m1328

[11] Prikaz Ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 9 noyabrya 2012 g. № 758n “Ob utverzhdenii standarta spetsializirovannoi meditsinskoi pomoshchi pri bolezni, vyzvannoi virusom immunodefitsita cheloveka (VICh-infektsii)” [Internet]. (In Russ). Available at: https://minzdrav.gov.ru/documents/8837-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-9-noyabrya-2012-g-758n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-bolezni-vyzvannoy-virusom-immunodefitsita-cheloveka-vich-infektsii.

[12] Приказ Министерства здравоохранения Российской Федерации от 9 ноября 2012 г. № 758н «Об утверждении стандарта специализированной медицинской помощи при болезни, вызванной вирусом иммунодефицита человека (ВИЧ-инфекции)» [интернет]. Режим доступа: https://minzdrav.gov.ru/documents/8837-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-9-noyabrya-2012-g-758n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-bolezni-vyzvannoy-virusom-immunodefitsita-cheloveka-vich-infektsii.

[13] Gerasimov AN, Morozova NI. Parametric and Nonparametric Methods in Medical Statistics. Epidemiology and Vaccinal Prevention. 2015;14(5):6–12. (In Russ). doi: 10.31631/2073-3046-2015-14-5-6-12

[14] Герасимов А.Н., Морозова Н.И. Параметрические и непараметрические методы в медицинской статистике // Эпидемиология и Вакцинопрофилактика. 2015. Т. 14, № 5. С. 6–12. doi: 10.31631/2073-3046-2015-14-5-6-12

[15] Chen R, Liang W, Jiang M, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. 2020;158(1):97–105. doi: 10.1016/j.chest.2020.04.010

[16] Chen R., Liang W., Jiang M., et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China // Chest. 2020. Vol. 158, N 1. P. 97–105. doi: 10.1016/j.chest.2020.04.010

[17] Nagibina MV, Smirnov NA, Bessarab TP, et al. Analysis of the course and outcomes of COVID-19 in HIV infected patients according to the infectious diseases’ hospital of Moscow. Clinical Medicine (Russian Journal). 2023;101(2-3):93–100. (In Russ). doi: 10.30629/0023-2149-2023-101-2-3-93-100

[18] Нагибина М.В., Смирнов Н.А., Бессараб Т.П., и др. Анализ течения и исходов COVID-19 у ВИЧ-инфицированных пациентов по данным инфекционного стационара города Москвы // Клиническая медицина. 2023. Т. 101, № 2-3. С. 93–100. doi: 10.30629/0023-2149-2023-101-2-3-93-100

[19] Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021;73(7):e1964–e1972. doi: 10.1093/cid/ciaa1339

[20] Dandachi D., Geiger G., Montgomery M.W., et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019 // Clin Infect Dis. 2021. Vol. 73, N 7. P. e1964–e1972. doi: 10.1093/cid/ciaa1339

[21] Yendewa GA, Perez JA, Schlick K, Tribout H, McComsey GA. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX). Open Forum Infect Dis. 2021;8(7):ofab272. doi: 10.1093/ofid/ofab272

[22] Yendewa G.A., Perez J.A., Schlick K., Tribout H., McComsey G.A. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX) // Open Forum Infect Dis. 2021. Vol. 8, N 7. P. ofab272. doi: 10.1093/ofid/ofab272

[23] Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022;19(1):3. doi: 10.1186/s12981-021-00427-y

[24] Danwang C., Noubiap J.J., Robert A., Yombi J.C. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis // AIDS Res Ther. 2022. Vol. 19, N 1. P. 3. doi: 10.1186/s12981-021-00427-y

[25] Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin Infect Dis. 2021;73(7): e2095–e2106. doi: 10.1093/cid/ciaa1605

[26] Geretti A.M., Stockdale A.J., Kelly S.H., et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study // Clin Infect Dis. 2021. Vol. 73, N 7. P. e2095–e2106. doi: 10.1093/cid/ciaa1605

[27] Kassanjee R, Davies MA, Ngwenya O, et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa. J Int AIDS Soc. 2023;26(6):e26104. doi: 10.1002/jia2.26104

[28] Kassanjee R., Davies M.A., Ngwenya O., et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa // J Int AIDS Soc. 2023. Vol. 26, N 6. P. e26104. doi: 10.1002/jia2.26104

[29] Sun J, Jiang R, Shao Y, et al. Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19. Chin Med J (Engl). 2023;136(22):2753–2755. doi: 10.1097/CM9.0000000000002902

[30] Sun J., Jiang R., Shao Y., et al. Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19 // Chin Med J (Engl). 2023. Vol. 136, N 22. P. 2753–2755. doi: 10.1097/CM9.0000000000002902

[31] Marmorino F, Salvatore L, Barbara C, et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer. 2017;116(3):318–323. doi: 10.1038/bjc.2016.413

[32] Marmorino F., Salvatore L., Barbara C., et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer // Br J Cancer. 2017. Vol. 116, N 3. P. 318–323. doi: 10.1038/bjc.2016.413

[33] Lu J, Wei Z, Jiang H, et al. Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study. J Surg Res. 2018;228:314–321. doi: 10.1016/j.jss.2018.03.035

[34] Lu J., Wei Z., Jiang H., et al. Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study // J Surg Res. Vol. 228. P. 314–321. doi: 10.1016/j.jss.2018.03.035

[35] Gulhar R, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: http://www.ncbi.nlm.nih.gov/books/NBK519570.

[36] Gulhar R., Ashraf M.A., Jialal I. Physiology, Acute Phase Reactants. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing, 2024. Available at: http://www.ncbi.nlm.nih.gov/books/NBK519570.

[37] Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5): 377–382. doi: 10.1136/thorax.58.5.377

[38] Lim W.S, van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study // Thorax. 2003. Vol. 58, N 5. P. 377–382. doi: 10.1136/thorax.58.5.377

RIGHTS & PERMISSIONS

Eco-vector